Liraglutide - Diabetes Mellitus
You are here : Home > Formulary Search > Liraglutide - Diabetes Mellitus
Status 1
- Subcutaneous injection (sc)
Documentation
PAD Profile
Other Indications
Below are listed other indications that Liraglutide is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Diabetes Mellitus.
- Acarbose
- Alogliptin
- Alogliptin/metformin
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Canagliflozin
- Canagliflozin/metformin
- Dapagliflozin
- Dapagliflozin/metformin
- Dulaglutide
- Empagliflozin
- Empagliflozin/metformin
- Ertugliflozin
- Exenatide
- Glibenclamide
- Gliclazide
- Glimepiride
- Glipizide
- Glyxambi (Linagliptin/empagliflozin)
- Insulin Aspart - Fiasp
- Insulin aspart - NovoRapid
- Insulin Aspart - Trurapi
- Insulin degludec
- Insulin degludec with liraglutide
- Insulin detemir
- Insulin glargine - Abasaglar
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Insulin Glargine - Toujeo
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Insulin Lispro - Humalog
- Insulin Lispro - Lyumjev
- Insulin pump - non-autoimmune causes
- Insulin pump - Type 1 diabetes
- Isophane (neutral insulin) - hypurin porcine 30/70
- Isophane Insulin - Humulin I
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Linagliptin
- Linagliptin/metformin
- Metformin hydrochloride
- Metformin hydrochloride/pioglitazone
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Pioglitazone hydrochloride
- Repaglinide
- Saxagliptin
- Saxagliptin/dapagliflozin
- Semaglutide
- Sitagliptin
- Soluble insulin - Hypurin porcine neutral
- Soluble insulin - Actrapid
- Soluble insulin - Humulin S
- Sotagliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Tirzepatide
- Tolbutamide
- Vildagliptin
Committee Recommendations (2)
Liraglutide is 1st-line for patients who wish to have a daily GLP-1 injection.
Dulaglutide continues to be the preferred GLP-1 where weekly injection is indicated.
Semaglutide is an alternative option for weekly injection.
Lixisenatide is no longer a preferred treatment but remains an option.
Treatment with GLP-1s should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance
A PREFERRED GLP-1 RECEPTOR AGONIST: Widely used, dose adjustment not required in severe renal impairment and has randomised controlled trial data to show improved cardiovascular outcomes Treatment should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance